Literature DB >> 2276822

Cardiobacterium hominis endocarditis in a patient with a hypersensitivity reaction to penicillin. Successful treatment with partial resection of the posterior mitral valve leaflet and antibiotic therapy with cefazolin.

R D Christen1.   

Abstract

A 43-year-old patient with preexisting mitral valve prolapse and Cardiobacterium hominis endocarditis with partial destruction of the posterior mitral valve leaflet is described. Successful treatment was achieved with partial resection of the posterior mitral valve leaflet and antibiotic therapy. Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin. No relapse of endocarditis was observed after 12 months of follow-up. Using micro broth dilution technique the isolated strain was shown to be most susceptible to penicillin G, cephalothin, and ciprofloxacin, with minimal inhibitory concentrations of 0.00025, 0.004, and 0.002 mg/l, respectively; and with minimal bactericidal concentrations (99.9% killing) of 0.25, 0.12, and 0.008 mg/l, respectively. We conclude that cephalosporins of the first generation or ciprofloxacin may be good alternatives to penicillin G in the treatment of C. hominis infection in patients known to be hypersensitive to penicillin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276822     DOI: 10.1007/bf01647009

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  FLUORESCENT ANTIBODY DETECTION OF HUMAN OCCURRENCE OF AN UNCLASSIFIED BACTERIAL GROUP CAUSING ENDOCARDITIS.

Authors:  I J SLOTNICK; J A MERTZ; M DOUGHERTY
Journal:  J Infect Dis       Date:  1964-12       Impact factor: 5.226

2.  Cardiobacterium hominis endocarditis.

Authors:  J Midgley; S P LaPage; B A Jenkins; G I Barrow; M E Roberts; A G Buck
Journal:  J Med Microbiol       Date:  1970-02       Impact factor: 2.472

3.  Embolomycotic aneurysm associated with bacterial endocarditis due to Cardiobacterium hominis.

Authors:  G D Perdue; E R Dorney; F Ferrier
Journal:  Am Surg       Date:  1968-12       Impact factor: 0.688

4.  Cardiobacterium hominis endocarditis.

Authors:  A I Snyder; P D Ellner
Journal:  N Y State J Med       Date:  1969-03-01

5.  Cardiobacterium hominis endocarditis manifesting as bacterial meningitis.

Authors:  P B Francioli; D Roussianos; M P Glauser
Journal:  Arch Intern Med       Date:  1983-07

6.  Cardiobacterium homonis endocarditis. Characterization of the unusual organisms and review of the literature.

Authors:  M Weiner; S Werthamer
Journal:  Am J Clin Pathol       Date:  1975-01       Impact factor: 2.493

7.  Cardiobacterium hominis endocarditis with cerebral mycotic aneurysm.

Authors:  J Laguna; B M Derby; R Chase
Journal:  Arch Neurol       Date:  1975-09

8.  Endocarditis due to Cardiobacterium hominis.

Authors:  R S Jobanputra; J Moysey
Journal:  J Clin Pathol       Date:  1977-11       Impact factor: 3.411

9.  Cardiobacterium hominis endocarditis. Four cases with clinical and laboratory observations.

Authors:  J E Geraci; P R Greipp; C J Wilkowske; W R Wilson; J A Washington
Journal:  Mayo Clin Proc       Date:  1978-01       Impact factor: 7.616

10.  Cardiobacterium hominis: review of microbiologic and clinical features.

Authors:  G P Wormser; E J Bottone
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
View more
  3 in total

1.  Infective endocarditis complicated with progressive heart failure due to beta-lactamase-producing Cardiobacterium hominis.

Authors:  P L Lu; P R Hsueh; C C Hung; L J Teng; T N Jang; K T Luh
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 2.  Cardiobacterium hominis endocarditis: Two cases and a review of the literature.

Authors:  A N Malani; D M Aronoff; S F Bradley; C A Kauffman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

3.  Cardiobacterium hominis endocarditis: A case report and review of the literature.

Authors:  Andrew Walkty
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-09       Impact factor: 2.471

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.